Inactive Instrument

Highlights MEDIGENE NA Swiss Exchange

Equities

OXMDGG

DE0005020903

End-of-day quote Swiss Exchange Other stock markets
- ^EUR	-

15/05	Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	CI
14/05	Medigene Ag Maintains Earnings Guidance for 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	15/05	CI
Medigene Ag Maintains Earnings Guidance for 2024	14/05	CI
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	02/05	CI
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	02/05	CI
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	25/04	CI
Rights Issue: 1 new share @ 1.2 EUR for 5 existing shares	24/04	FA
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	08/04	CI
Medigene Gets European Patent for T-Cell Receptor Technology	04/04	MT
Medigene AG Secures European Patent for Its iM-TCR Technology	04/04	CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Medigene Ag Provides Earnings Guidance for 2024	28/03	CI
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	04/03	CI
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	12/02	CI
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	21/11	CI
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	04/11	CI
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23/23/23	CI
Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023	16/23/16	CI
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types	23/23/23	CI
Medigene AG Provides Revenue Guidance for 2023	17/23/17	CI
Medigene AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MEDIGENE NA Swiss Exchange

Equities

OXMDGG

DE0005020903

Highlights

Filters